Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Doctors and advocates urge fewer buprenorphine barriers; committee took testimony but did not vote
Summary
Physicians and addiction experts told the House committee that buprenorphine expands access to treatment for opioid use disorder and urged removing prescriptive, visit-frequency and urine-screening mandates. The committee held the bill for discussion and asked the Board of Medical Licensure to consider regulatory changes.
The House Standing Committee on Health Services held a discussion on House Bill 788, a measure lawmakers described as intended to reduce regulatory barriers to prescribing buprenorphine for opioid-use disorder. The committee did not take a vote on the bill but invited medical experts to answer questions.
Dr. Pat Murphy, regional director of the American Society of Addiction Medicine and a professor at the University of Louisville, described buprenorphine as a partial opioid with a ceiling effect that reduces overdose risk compared with methadone. “If everyone who needs this medication could have access…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
